Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793148 | 0.91 | RIPK1 (0.43) | LMNAL3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL1300316 | 0.90 | CNR2 (0.42) | KMT2AALDH1A1KDM4EMEN1TSHR | |
| SCHEMBL2960988 | 0.84 | BCHE (0.47) | LMNAL3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL14175046 | 0.82 | ADORA1 (0.43) | LMNAL3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL2964616 | 0.81 | — | — | |
| SCHEMBL24134198 | 0.80 | RIPK1 (0.37) | LMNAL3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL16377844 | 0.79 | KMT2A (0.48) | LMNAL3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL23432880 | 0.79 | HSD17B10 (0.38) | LMNAKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL2960396 | 0.79 | BCHE (0.49) | L3MBTL1KMT2AALDH1A1MEN1TSHR | |
| SCHEMBL20337466 | 0.78 | LMNA (0.43) | LMNAL3MBTL1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322996-A1 | POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE | LIFE TECHNOLOGIES AS (NO) | 2023-10-12 | — | — | US | disclosed |
| US-20230322996-A1 | POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE | LIFE TECHNOLOGIES AS (NO) | 2023-10-12 | — | — | US | disclosed |
| WO-2023079524-A2 | POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE | LIFE TECHNOLOGIES AS (NO) | 2023-05-11 | — | — | WO | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-8476445-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100137605-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7678915-B2 | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070010677-A1 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20050209279-A1 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-6919458-B2 | Process for production of piperidine derivatives | AMR TECHNOLOGY, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-0868182-B1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030028029-A1 | Process for production of piperidine derivatives | BARCLAYS BANK PLC, AS THE COLLATERAL AGENT | 2003-02-06 | — | — | US | disclosed |
| US-6458958-B1 | PROCESS OF PREPARING A PIPERIDINE DERIVATIVE COMPOUND OF THE FORMULA: ACYLATING AN .ALPHA.,.ALPHA.-DISUBSTITUTED-METHYLBENZENE DERIVATIVE HAVING THE FORMULA: | ALBANY MOLECULAR RESEARCH, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6444824-B1 | ANTISEROTONINE AGENTS; SIDE EFFECT REDUCTION | ALBANY MOLECULAR RESEARCH, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6153754-A | Process for production of piperidine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0868182-A4 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0868182-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1998-10-07 | — | — | EP | disclosed |
| WO-1997023213-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997009983-A1 | PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PRODUCTION | ALBANY MOLECULAR RESEARCH, INC. (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137605-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | HPD, PTMA, HAAO | LMNA 2264/4885L3MBTL1 4045/4885KMT2A 116/4885 |
| US-20050209279-A1 | Process for production of piperidine derivatives | NR5A2, NR4A1, NR4A2 | LMNA 4554/4885L3MBTL1 3769/4885KMT2A 1485/4885 |
| US-20070010677-A1 | Process for production of piperidine derivatives | NR4A1, NR5A2, NR4A2 | LMNA 4425/4885L3MBTL1 4065/4885KMT2A 2008/4885 |
| US-20030028029-A1 | Process for production of piperidine derivatives | NR4A1, RCOR1, CBR1 | LMNA 4153/4885L3MBTL1 4263/4885KMT2A 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.